A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62.
Fu-Cheng WangBin PengTing-Ting RenShao-Peng LiuJing-Rui DuZi-Hao ChenTing-Ting ZhangXiaoyang GuMo LiSheng-Li CaoXingzhi XuPublished in: Journal of medicinal chemistry (2022)
Quinazoline and its derivatives have drawn much attention in the development of potential antitumor agents. Here, we synthesized a series of 1,2,3-triazole derivatives of quinazoline at the C6 position and evaluated for their cytotoxic activity in various human cancer cell lines. We found that compound 5a was the most cytotoxic to HCT-116 cells (IC 50 , 0.36 μM). Target profiling found that 5a directly binds to both the autophagy-associated protein SQSTM1/P62 and the E3 ligase RNF168, promoting their interaction. Consistently, 5a treatment induces a decrease in RNF168-mediated H2A ubiquitination and compromises homologous recombination-mediated DNA repair, thus increasing the sensitivity of HCT-116 to X-ray radiation. Moreover, 5a suppressed xenografted tumor growth in mice in a dose-dependent manner. Taken together, the 1,2,3-triazole derivative of quinazoline 5a may serve as a novel compound for tumor therapy based on its role in promoting a P62/RNF168 interaction.
Keyphrases
- dna repair
- dna damage response
- cell cycle arrest
- dna damage
- cell death
- induced apoptosis
- endothelial cells
- papillary thyroid
- oxidative stress
- pi k akt
- working memory
- signaling pathway
- high resolution
- single cell
- magnetic resonance imaging
- type diabetes
- combination therapy
- metabolic syndrome
- cell proliferation
- induced pluripotent stem cells
- skeletal muscle
- magnetic resonance
- water soluble
- adipose tissue
- childhood cancer
- bone marrow
- replacement therapy